Dr. Naidoo Discusses the Management of Immune-Related Adverse Events in Lung Cancer

Jarushka Naidoo, MBBCh
Published: Saturday, Mar 10, 2018



Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.

In the past few years, there have been several guidelines published to assist physicians with diagnosing and identifying immune-related side effects. Pneumonitis is the most common irAE seen in patients with lung cancer, Naidoo says, and it can be difficult to discern the difference between pneumonitis and pneumonia or progression of lung cancer.

It is widely accepted practice now that patients receive a high-resolution CT scan, but they can have a chest xray to start. Patients who are symptomatic should be considered for a bronchoscopy with or without a lung biopsy in order to tell if a patient has pneumonitis.
 


Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.

In the past few years, there have been several guidelines published to assist physicians with diagnosing and identifying immune-related side effects. Pneumonitis is the most common irAE seen in patients with lung cancer, Naidoo says, and it can be difficult to discern the difference between pneumonitis and pneumonia or progression of lung cancer.

It is widely accepted practice now that patients receive a high-resolution CT scan, but they can have a chest xray to start. Patients who are symptomatic should be considered for a bronchoscopy with or without a lung biopsy in order to tell if a patient has pneumonitis.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x